All In Biotech

NDA 206473 · Hospira

Linezolid In Sodium Chloride 0.9% In Plastic Container

Linezolid · Intravenous · Oxazolidinone Antibacterial

Last checked: Nov 20, 2026Latest source record: Jun 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jun 18, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

179

68 Phase 3, 26 recruiting

FAERS reports

23,980

22,401 serious, 4,476 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 19, 2026.

Linezolid injection is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.4 ) Limitations of Use: ( 1.5 ) • Linezolid injection is not indicated for the treatment of Gram-negative infections. • The safety and efficacy of Linezolid formulations given for longer than 28 days have not been evaluated in controlled clinical trials. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Linezolid injection formulations and other antibacterial drugs, Linezolid injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) 1.1 Nosocomial Pneumonia Linezolid injection is indicated for the treatment of nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae [ see Clinical Studies (14) ]. 1.2 Community-acquired Pneumonia Linezolid injection is indicated for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae , including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible isolates only) [ see Clinical Studies (14) ]. 1.3 Complicated Skin and Skin Structure Infections Linezolid injection is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus...

Mechanism: Linezolid is an antibacterial drug [ see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 18, 2015 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · LINEZOLID 600MG/300ML (2MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Linezolid" as an intervention, any sponsor and status, largest first.

All 179 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,355
  • drug ineffective1,888
  • thrombocytopenia1,797
  • anaemia1,498
  • drug interaction1,199
  • nausea1,065
  • lactic acidosis927
  • vomiting893
  • neuropathy peripheral892
  • acute kidney injury891
  • pyrexia834
  • serotonin syndrome818

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200457
200577
2006197
2007178
2008158
2009189
2010175
2011245
2012245
2013255
2014290
2015330
2016705
20171,000
20182,433
20192,016
20202,181
20211,830
20222,198
20232,231
20242,466
20252,434
20262,090

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 459 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.